This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synutra Chairman Issues Statement On Product Safety

QINGDAO, China and ROCKVILLE, Md., Jan. 12, 2012 /PRNewswire-Asia/ -- Synutra International, Inc. (NASDAQ: SYUT), ("Synutra" or the "Company"), which owns subsidiaries in China that produce, market and sell nutritional products for infants, children and adults, today issued a statement in response to local Chinese media reports of a pair of 4-month old twins in Jiangxi province who became ill with severe intestinal symptoms. One passed away from dehydration on January 7, 2012. The other has recovered following hospitalization. Both children were reported to have been consuming Synutra powdered milk formula products for weeks before the sudden onset of their illnesses.

Mr. Liang Zhang, Chairman and CEO of Synutra, stated, "Our hearts go out to the family suffering from this tragic event. At the same time, we firmly believe this is an isolated incident unrelated to Synutra's products.  All of our products, including the lot under question, are thoroughly tested and analyzed before shipment. These products are formulated and produced under stringent safety standards to safely meet the nutritional needs of infants.  We have chosen to not recall any of our products because we are confident that they are safe. We are also not aware of any decisions to remove our products from store shelves, except in the store from which the ill infants' formula originated.

"The Company and our distributors are actively cooperating with various local and provincial authorities to investigate the source of the reported illness," continued Mr. Zhang. "The Jiangxi Bureau of Quality and Technical Supervision is in the process of testing product samples collected from the affected family.  We recognize the pain of the grieving family. However, we hope to reassure consumers that we are fully confident that our products are safe.  We believe in the quality of our products and stand by our quality assurances," Mr. Zhang concluded.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $247.54 -0.07%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs